Bülent Ündar

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Hydroxyurea treatment for chronic myeloid leukemia during pregnancy

Murat Celıloğlu, Sabahattin Altunyurt, Bülent Ündar · Acta Obstetricia Et Gynecologica Scandinavica · 2000 · 55 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Medicine +6

Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers

İnci Alacacıoğlu, Güner Hayri Özsan, Bahriye Payzın et al. · Chemotherapy · 2014 · 29 citations

Can Neutrophil‐to‐Lymphocyte Ratio, Monocyte‐to‐Lymphocyte Ratio, and Platelet‐to‐Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?

Şerife Solmaz, Celal Acar, Aybüke Olgun et al. · Clinical Transplantation · 2018 · 26 citations

Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders

Mehmet Ali Özcan, Abdurrahman Çömlekçi, Fatih Demırkan et al. · Thrombosis Research · 2003 · 23 citations

Plasma Levels, Thyroid Disease, Parathyroid Hormone +6